- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05920941
Mass Balance Study of [14C]JAB-21822
February 3, 2024 updated by: Jacobio Pharmaceuticals Co., Ltd.
Mass Balance Study of [14C]JAB-21822 in China Healthy Subjects
Mass Balance Study of [14C]JAB-21822 in China Healthy Subjects
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A phase I study to quantify the total mass balance in healthy subjects after a single dose of [14C]JAB-21822
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- The First Affiliated Hospital of Soochow University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male subjects between the ages of 18 and 45 years (inclusive).
- Subjects weighing ≥ 50 kg and Body Mass Index of 19.0 to 26.0 kg/m2.
- Subjects who have voluntarily participated in the study and signed the informed consent form with good compliance.
Exclusion Criteria:
- With abnormal and clinically significant comprehensive physical examinations, vital signs, or laboratory examinations.
- Has a positive test for HBV, HCV, HIV, or syphilis.
- Known medical history judged by the investigator as not suitable for the study.
- Known history of drug or food allergy.
- Has drug or alcohol abuse history or positive drug or alcohol abuse test results.
- Heavy smokers or caffeine addicts.
- Has diseases or other conditions affecting the absorption, distribution, metabolism, and excretion of oral drugs.
- Disagree to strict contraception within one year after the trial
- Has any other conditions judged by the investigator as not suitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]JAB-21822
Single oral dose of 800mg 14C]JAB-2182 suspension
|
Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery of total radioactivity in urine and fecal samples
Time Frame: up to 504 hours post dose
|
Mass balance recovery of total radioactivity in urine and fecal samples
|
up to 504 hours post dose
|
Total radioactivity in plasma PK: Cmax
Time Frame: up to 504 hours post dose
|
Highest radioactivity observed plasma concentration
|
up to 504 hours post dose
|
Total radioactivity in plasma PK: Area under the curve
Time Frame: up to 504 hours post dose
|
Area under the plasma concentration time curve
|
up to 504 hours post dose
|
Total radioactivity in plasma PK: t1/2
Time Frame: up to 504 hours post dose
|
Elimination half-life
|
up to 504 hours post dose
|
Total radioactivity in plasma PK: MRT
Time Frame: up to 504 hours post dose
|
Mean residence time
|
up to 504 hours post dose
|
Total radioactivity in plasma PK: Tmax
Time Frame: up to 504 hours post dose
|
Time for Cmax
|
up to 504 hours post dose
|
Percentage of radioactivity and identification of metabolites in plasma, urine and fecal samples
Time Frame: up to 504 hours post dose
|
Percentage of prototype drugs and its metabolites in plasma, urine and fecal samples.
Identification of the major metabolites
|
up to 504 hours post dose
|
Whole blood to plasma total radioactivity ratio
Time Frame: up to 504 hours post dose
|
up to 504 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
JAB-21822 PK: Cmax
Time Frame: up to 504 hours post dose
|
Highest observed plasma concentration of JAB-21822
|
up to 504 hours post dose
|
JAB-21822 PK: Area under the curve
Time Frame: up to 504 hours post dose
|
Area under the plasma concentration time curve of JAB-21822
|
up to 504 hours post dose
|
JAB-21822 PK: t1/2
Time Frame: up to 504 hours post dose
|
Elimination half-life of JAB-21822
|
up to 504 hours post dose
|
JAB-21822 PK: MRT
Time Frame: up to 504 hours post dose
|
Mean residence time of JAB-21822
|
up to 504 hours post dose
|
JAB-21822 PK: Tmax
Time Frame: up to 504 hours post dose
|
Time for Cmax of JAB-21822
|
up to 504 hours post dose
|
Number of participants with adverse events
Time Frame: up to 504 hours post dose
|
All subjects will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms and ophthalmological assessments
|
up to 504 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Jacobio Pharmaceuticals, Jacobio Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2023
Primary Completion (Actual)
August 9, 2023
Study Completion (Actual)
August 9, 2023
Study Registration Dates
First Submitted
June 6, 2023
First Submitted That Met QC Criteria
June 25, 2023
First Posted (Actual)
June 27, 2023
Study Record Updates
Last Update Posted (Actual)
February 6, 2024
Last Update Submitted That Met QC Criteria
February 3, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- JAB-21822-1008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mass Balance Study in Healthy Subjects
-
Shanghai Henlius BiotechCompletedMass Balance Study in Healthy SubjectsChina
-
Clavis PharmaCompletedNot Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy SubjectsUnited Kingdom
-
InventisBio Co., LtdCompleted
-
H. Lundbeck A/SCompletedBioequivalence Study in Healthy SubjectsRussian Federation
-
AstraZenecaCompletedHealthy Volunteers | Mass Balance StudyUnited States
-
University of Rennes 2Ecole normale supérieure de Rennes (FRANCE)RecruitingValidity Study of Activity Monitors in Healthy SubjectsFrance
-
Medical University of ViennaVienna University of TechnologyUnknownModulation of Cardiovascular Parameters and Sympathovagal Balance in Healthy SubjectsAustria
-
Perseverance Research Center, LLCHDCCompletedStudy Subjects Currently Enrolled in a Clinical Research TrialUnited States
-
University of ZurichSwiss Federal Institute of TechnologyCompletedHealthy Subjects | Mass Spectrometry | Exhaled BreathSwitzerland
-
University Medicine GreifswaldCompletedImpact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers (BERKI-1)Pharmacokinetic Study in Healthy VolunteersGermany
Clinical Trials on [14C]JAB-21822
-
Jacobio Pharmaceuticals Co., Ltd.Completed
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingColorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12CChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | Solid Tumor | CRCChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingPancreatic Cancer | KRAS P.G12CChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingAdvanced Colorectal Cancer | Small Intestinal Cancer | Appendiceal CancerChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | Advanced Solid Tumor | CRCUnited States
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MFChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingSolid Tumors, AdultUnited States
-
Jacobio Pharmaceuticals Co., Ltd.Not yet recruiting